Screening populations at low risk carries high risks

doi:10.1136/bmj.326.7379.53

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Luc Bonneux, associate professor (l.bonneux@jc.azu.nl)

Julius Center for Health Sciences, Utrecht Medical Center, HP D 01.335, PO Box 85500NL-3508 GA Utrecht, Netherlands

EDITOR—In their key points Lu-Yao et al say that the lack of association between more intensive screening and treatment and lower mortality from prostate cancer means that trials should continue to settle this question.1 More research is the classic conclusion of all studies, but is it true?

Firstly, trials cannot be used to prove that something does not work. That is unethical; there has to …